Heart Failure with Preserved Ejection Fraction Is Really a Metabolic Disease | Research

The takeaway

A comprehensive review reframes HFpEF as a systemic cardio-metabolic disorder, highlighting the promise of GLP-1 RAs and SGLT2 inhibitors over traditional heart failure drugs.

Metabolic reframing
HFpEF driven by visceral fat, insulin resistance, and inflammation — metabolic drugs outperform neurohormonal approaches

What the researchers found

HFpEF is better understood as a systemic cardio-metabolic disorder where GLP-1 RAs and SGLT2 inhibitors show benefit by targeting underlying metabolic dysfunction rather than neurohormonal pathways.

Why it matters

HFpEF affects millions and has historically had no effective treatment. Reconceptualizing it as a metabolic disease finally provides a rational treatment framework.

How the study worked

Systematic search of PubMed, Scopus, and Web of Science (2000-2025); 108 studies selected from ~800 screened; RCTs, cohorts, and mechanistic reports.

What this study cannot tell us

Review — while comprehensive, the metabolic framework may oversimplify HFpEF heterogeneity; not all HFpEF patients have metabolic phenotype.

How to read the evidence

Comprehensive review screening ~800 records — strong evidence synthesis with systematic methodology.

When this study was published

Published 2026 in Cureus. Literature through 2025.

The bigger picture

The metabolic reframing of HFpEF is transforming cardiology — explaining why diabetes drugs work for a heart condition and potentially explaining decades of failed HFpEF trials.

Questions still open

Should HFpEF treatment algorithms prioritize metabolic therapies over traditional heart failure drugs?
Can metabolic phenotyping guide treatment selection for individual HFpEF patients?

Common questions

What is HFpEF?

Heart failure with preserved ejection fraction is a type of heart failure where the heart pumps normally but can't relax properly. It's very common and was previously considered untreatable.

Why do diabetes drugs help a heart condition?

This review explains that HFpEF is fundamentally a metabolic disease — driven by belly fat, insulin resistance, and inflammation. Drugs targeting these metabolic problems (GLP-1 RAs, SGLT2i) address the root cause.

Read the original research

The Metabolic Heart: Reframing Heart Failure With Preserved Ejection Fraction as a Systemic Cardio-Metabolic Syndrome.

Cureus, 18(1), e100590

View on PubMed ↗Publisher’s paper ↗

Citation

Baidya, Debasrita; Hanumanpratap Singh Kshatri, Abhishek; Zerzan, Emi K; Menon, Gayathri J; Sawale, Mihika; Subhash Bhalodiya, Sunny. (2026). The Metabolic Heart: Reframing Heart Failure With Preserved Ejection Fraction as a Systemic Cardio-Metabolic Syndrome.. Cureus, 18(1), e100590. https://doi.org/10.7759/cureus.100590